Method for purifying Fc region-modified antibodies

The use of a modified protein A ligand with specific amino acid substitutions in the C or Z domain of Staphylococcus protein A addresses the inefficiencies in purifying pI-modified antibodies, allowing for effective industrial-scale production.

JP7583411B2Active Publication Date: 2024-11-14CHUGAI PHARMA CO LTD +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2021513692
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-04-10
Filing Date
2020-04-09
Publication Date
2024-11-14
Estimated Expiration
2040-04-09

AI Technical Summary

Technical Problem

Existing methods for purifying antibodies with amino acid modifications, particularly those affecting the isoelectric point (pI), are inefficient and unsuitable for industrial-scale production using conventional protein A columns.

Method used

A method utilizing a resin with a modified protein A ligand, specifically designed to bind to antibodies with Q311R and P343R substitutions, by replacing lysine residues at key positions in the C or Z domain of Staphylococcus protein A with alternative amino acids, enabling efficient purification through affinity chromatography.

Benefits of technology

Enables the simple and efficient purification of pI-modified antibodies that cannot be effectively purified with standard protein A columns, facilitating industrial-scale production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007583411000007
    Figure 0007583411000007
  • Figure 0007583411000008
    Figure 0007583411000008
  • Figure 0007583411000009
    Figure 0007583411000009
Patent Text Reader

Abstract

In the present invention, an affinity purified resin having sufficient binding affinity for a modified Fc region having reduced bindability with protein A was found. Specifically, immunoglobulin containing a modified Fc region having reduced bindability with protein A was successfully purified, where a protein A-modified ligand including a structure in which an amino acid of the C domain has been substituted serves as the Fc ligand.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for purifying an antibody, and more particularly to a purification method for an antibody having an Fc region modified with specific amino acid mutations. [Background technology]

[0002] Advances in recombinant gene technology have made it possible to provide a stable supply of various protein preparations, and the development of a variety of antibody drugs is progressing.

[0003] When producing antibodies using recombinant DNA technology with mammalian cells as hosts, the antibodies are purified by various types of chromatography after treatment with Protein A or Protein G affinity column chromatography, taking advantage of the property of Protein A or Protein G binding to the Fc chain of IgG. In particular, antibody purification by Protein A affinity column chromatography is the process most commonly used in the production of antibody drugs in order to recover antibodies from the culture medium.

[0004] For example, in JP-A-5-504579 (Patent Document 1), an antibody-containing aqueous medium obtained from mammalian cell culture is applied to Protein A or Protein G column chromatography to adsorb the antibody onto the column, and then the antibody is eluted using an acidic solution (citric acid at a concentration of about 0.1 M, pH 3.0-3.5), and the resulting acidic eluate is purified by sequentially applying it to ion exchange column chromatography and size exclusion column chromatography.

[0005] On the other hand, for the purpose of improving blood retention or pharmacokinetics, an amino acid substitution technique for controlling the isoelectric point (pI) of an antibody, specifically, a technique for controlling the pI of an antibody by modifying amino acid residues exposed on the surface of the antibody, is known (WO 07 / 114319 (Patent Document 2), WO2017 / 104783 (Patent Document 3)). Patent Document 2 discloses that by modifying the amino acid residues of an antibody to control the pI, it is possible to improve the plasma retention and half-life of the antibody, leading to a reduction in the dosage of the antibody as a pharmaceutical and an extension of the administration interval. In addition, Patent Document 3 discloses that by modifying the CH2 and CH3 regions of the antibody to increase the pI by introducing amino acid substitutions Q311R and P343R, the disappearance of antigens from plasma can be promoted when the antibody is administered in vivo.

[0006] Protein A, which is used to purify antibodies, is a protein present in the cell wall of Staphylococcus aureus and binds to immunoglobulins, especially the Fc region of IgG. Staphylococcus-derived protein A proteins generally have a repeat structure of five homologous immunoglobulin-binding domains called E, D, A, B, and C domains, and each binding domain is capable of binding to an immunoglobulin by itself. In addition to natural protein A, recombinant proteins consisting of only immunoglobulin-binding domains with partially modified amino acids are also used as affinity ligands for affinity chromatography. For example, protein A columns have been developed that aim to improve the efficiency of antibody purification by modifying the C domain of staphylococcal protein A by substituting alanine for glycine at position 29 of the amino acid sequence of the C domain, or by substituting alanine for glycine at position 29 of the amino acid sequence of the B domain in which one or more of the native lysines at positions 4, 7, and 35 of the Z domain are replaced with amino acids other than lysine (Patent Documents 4 and 5). [Prior art documents] [Patent documents]

[0007] [Patent Document 1] Special Publication No. 5-504579 [Patent Document 2] WO07 / 114319 publication [Patent Document 3] WO2017 / 104783 publication [Patent Document 4] JP 2007-252368 A [Patent Document 5] WO2015 / 034000 publication Summary of the Invention [Problem to be solved by the invention]

[0008] Protein A has been used as a ligand for antibody purification. However, no detailed investigation has been done on purification methods suitable for antibodies with amino acid modifications for pI modification (hereinafter referred to as pI modified antibodies), or on problems in the purification process. Therefore, for example, it was not known that there exist antibodies that cannot be purified using commonly used Protein A columns.

[0009] The present inventors have found that there are pI modified antibodies that cannot be efficiently purified using commonly used Protein A columns. Thus, an efficient purification method suitable for such antibodies is needed. In other words, an objective of the present invention is to provide a highly efficient and economical purification method that enables the industrial-scale production of pI modified antibodies that cannot be efficiently purified using commonly used Protein A columns. [Means for solving the problem]

[0010] As a result of intensive research to achieve the above-mentioned objective, the present inventors have found that even pI-modified antibodies that cannot be efficiently purified using commonly used Protein A columns can be efficiently purified by using a resin having a specific modified Protein A ligand.

[0011] That is, the present invention provides the following [1] to

[20] . [1] A method for purifying an IgG antibody comprising amino acid substitutions of Q311R and P343R from a composition containing the antibody, comprising: (a) preparing an affinity column comprising a carrier on which a modified protein A ligand is immobilized, the modified immunoglobulin-binding domain comprising a modification in which any one or more of the original lysine residues at positions 4, 7 and 35 of the modified Staphylococcus protein A C domain defined in SEQ ID NO:1 or the Z domain defined in SEQ ID NO:2 are substituted with amino acid residues other than lysine, or a multimer of such modified immunoglobulin-binding domain; (b) loading the composition containing the IgG antibody onto the affinity column of step (a); and (c) eluting and recovering the IgG antibodies from the affinity column of step (b). [2] The method according to [1], wherein the modified immunoglobulin-binding domain multimer is a 2- to 10-mer and comprises, at the first and / or second position from the N-terminus or C-terminus, a modified C domain (SEQ ID NO: 1) or an immunoglobulin-binding domain in which at least one of the original amino acid residues at positions 40, 43, 46, 53, 54, and 56 in the Z domain (SEQ ID NO: 2) has been substituted with a lysine residue. [3] The method according to [1] or [2], wherein the substitution is a modification in which one or more of the original lysine residues at positions 4, 7, and 35 of the variant C domain or Z domain of protein A are substituted with any amino acid residue selected from the group consisting of alanine residues (A), glutamine residues (Q), asparagine residues (D), valine residues (V), serine residues (S), threonine residues (T), histidine residues (H), tyrosine residues (Y), arginine residues (R), glutamic acid residues (E), phenylalanine residues (F), leucine residues (L), isoleucine residues (I), and proline residues (P). [4] The method according to any one of [1] to [3], wherein the modified immunoglobulin-binding domain is (i) a modified immunoglobulin-binding domain having the amino acid sequence shown in SEQ ID NO: 3 or 5, or (ii) a modified immunoglobulin-binding domain comprising an amino acid sequence in which one or several amino acid residues other than those at positions 4, 7, and 35 in the amino acid sequence shown in SEQ ID NO: 3 or 5 have been substituted, deleted, added, and / or inserted. [5] The method according to any one of [1] to [4], wherein the modified immunoglobulin-binding domain has the ability to bind to an IgG antibody comprising substitutions of amino acid residues Q311R and P343R. [6] The modified protein A ligand is a modified ligand comprising a modified immunoglobulin-binding domain consisting of at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4, and 5, 5 ] [7] The method according to any one of [1] to [6], wherein the modified protein A ligand is immobilized on the carrier by any means selected from the group consisting of the following (1) to (5): (1) Protein A C domain Modified form or a method of immobilizing the antibody on a carrier via a modified immunoglobulin-binding domain in which one to six of the amino acid residues at positions 40, 43, 46, 53, 54, and 56 in the Z domain have been additionally substituted with lysine residues; (2) A method in which cysteine ​​is introduced at the C-terminus of Protein A and immobilized to a carrier via a disulfide bond or a thioether bond; (3) A method of immobilizing the thiol group on an amino group-containing solid support by cyanating the thiol group; (4) A method for immobilizing a multimer of a modified immunoglobulin binding domain having cysteine ​​residues to an amino group-containing support using 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) as a crosslinking agent; and (5) A method of immobilizing a modified immunoglobulin-binding domain to a carrier via multiple lysine residues added to the C-terminus of a modified immunoglobulin-binding domain in which the lysine residues at positions 42, 49, 50, and 58 of a modified C domain of protein A have been replaced with amino acids other than lysine residues, or a modified immunoglobulin-binding domain in which the lysine residues at positions 49, 50, and 58 of the Z domain have been replaced with amino acids other than lysine. [8] The method according to any one of [1] to [7], wherein the IgG antibody further comprises a substitution of one or more amino acid residues selected from M428L, N434A, Y436T, Q438R, and S440E in the CH3 region of the IgG antibody. [9] The method according to any one of [1] to [8], wherein the CH3 region of the IgG antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6 to 11.

[10] The method according to any one of [1] to [9], wherein the heavy chain constant region of the IgG antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 12 to 57.

[11] The method according to any one of [1] to

[10] , wherein the IgG antibody has a pI value of 4.0 to 10.0.

[12] The method according to any one of [1] to

[11] , wherein the binding ability of the modified protein A ligand to the Fc region of the IgG antibody is 5-fold or more compared to the binding ability of unmodified protein A.

[13] The method according to any one of [1] to

[12] , further comprising a step of washing the affinity column with a washing solution prior to step (c).

[14] The method according to

[13] , wherein the washing solution is a combination of a buffer and a salt, the buffer comprising at least one selected from the group consisting of phosphoric acid, acetic acid, citric acid, glycine, and trishydroxymethylaminomethane, and the salt comprising at least one selected from the group consisting of arginine, sodium chloride, and sodium sulfate.

[15] The method according to any one of [1] to

[14] , further comprising, after step (c), a step of purifying the IgG antibody by at least one chromatography selected from the group consisting of cation exchange chromatography, anion exchange chromatography, hydrophobic interaction chromatography, multimode chromatography, and hydroxyapatite chromatography.

[16] The method according to any one of [1] to

[15] , wherein step (c) comprises eluting the IgG antibody from the affinity column with an elution solution containing at least one selected from the group consisting of hydrochloric acid, acetic acid, citric acid, arginine, glycine, and phosphoric acid.

[17] The method according to any one of [1] to

[16] , wherein the antibody is a humanized antibody or a human antibody.

[18] The method according to any one of [1] to

[17] , wherein the antibody is an anti-myostatin antibody, an anti-IL-6 receptor antibody, an anti-IL-6 antibody, an anti-IL-8 antibody, or an anti-IL-31 receptor antibody.

[19] Use of an affinity column comprising a carrier on which a protein A modified ligand is immobilized in the purification of an IgG antibody comprising substitutions of amino acid residues Q311R and P343R, wherein the protein A modified ligand comprises either or both of a modified protein A C domain and / or Z domain in which amino acids have been substituted, the substitutions being substitutions in which one or more of the original lysine residues at positions 4, 7 and 35 of the modified C domain or Z domain are modified to amino acid residues other than lysine, and the modified ligand has the ability to bind to the IgG antibody.

[20] A method for producing an IgG antibody having amino acid residue substitutions of Q311R and P343R, comprising the steps of: (i) providing a composition containing an IgG antibody comprising amino acid residue substitutions Q311R and P343R; (ii) preparing an affinity column comprising a carrier on which a modified protein A ligand is immobilized, the modified immunoglobulin-binding domain comprising a modification in which any one or more of the original lysine residues at positions 4, 7 and 35 of the modified Staphylococcus protein A C domain defined in SEQ ID NO:1 or the Z domain defined in SEQ ID NO:2 are substituted with amino acid residues other than lysine, or a multimer of such modified immunoglobulin-binding domain; (iii) loading the composition containing the IgG antibody onto the affinity column of step (ii); and (iv) eluting and recovering the IgG antibody from the affinity column loaded with the composition containing the IgG antibody in step (iii). Alternatively, the present invention relates to [1'] A method for purifying an IgG antibody comprising amino acid substitutions of Q311R and P343R from a composition containing the antibody, comprising: (a) preparing an affinity column comprising a carrier having a Protein A modified ligand immobilized thereon; (b) loading the composition containing the IgG antibody onto the affinity column of step (a); and (c) eluting and recovering the IgG antibody from the affinity column of step (b), wherein the Protein A modified ligand comprises either or both of a modified C domain and a modified Z domain of Protein A in which amino acids have been substituted, the substitutions comprising modifying one or more of the original lysine residues at positions 4, 7 and 35 of the modified C domain or the Z domain to amino acid residues other than lysine, and the Protein A modified ligand has the ability to bind to the IgG antibody. Effect of the Invention

[0012] According to the present invention, even pI-modified antibodies that cannot be successfully purified using a conventional Protein A column can be purified simply and efficiently. [Brief description of the drawings]

[0013] [Figure 1] 1 shows the results of measuring the dynamic binding capacity (DBC) of an antibody containing no modification in the Fc region on each Protein A immobilized resin, in which the vertical axis represents DBC (g / L resin) and the horizontal axis represents residence time (minutes). [Figure 2-1] 1 shows the results (real-time binding curve) of the binding affinity between the ligand of AF-rProtein A HC-650F (structure shown in formula (1')) and the antibody evaluated using the BLItz (registered trademark) (ForteBio) evaluation system. [Figure 2-2] The binding affinity between the MabSelect SuRe ligand and antibody was evaluated using the BLItz (registered trademark) (ForteBio) evaluation system (real-time binding curve). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] The present invention will be described in detail below. The present invention relates to a method for purifying a composition containing an antibody with an increased isoelectric point (pI), specifically, the present invention relates to a method for purifying an IgG antibody comprising amino acid substitutions Q311R and P343R from a composition containing the antibody, the method comprising: (a) preparing an affinity column comprising a carrier on which a modified protein A ligand is immobilized, the modified immunoglobulin-binding domain comprising a modification in which any one or more of the original lysine residues at positions 4, 7 and 35 of the modified Staphylococcus protein A C domain defined in SEQ ID NO:1 or the Z domain defined in SEQ ID NO:2 are substituted with amino acid residues other than lysine, or a multimer of such modified immunoglobulin-binding domain; (b) loading the composition containing the IgG antibody onto the affinity column of step (a); and (c) eluting and recovering the IgG antibody loaded in step (b).

[0015] The IgG antibody of the present invention containing substitutions of amino acid residues Q311R and P343R in the CH2 and CH3 regions is one in which glutamine (Q) at position 311 in the CH2 and CH3 regions of the parent Fc region is modified to arginine (R) and proline (P) at position 343 in the CH2 and CH3 regions of the parent Fc region are modified to arginine (R) according to EU numbering. Generally, the CH2 region corresponds to positions 231 to 340 in the hinge region according to EU numbering, and the CH3 region corresponds to positions 341 to 447 in the EU numbering. The "parent Fc region" in this application refers to the Fc region before the introduction of the amino acid modifications described herein. Preferred examples of the parent Fc region include Fc regions derived from natural antibodies. The antibody may be derived from a human or a monkey (e.g., a cynomolgus monkey, a rhesus monkey, a marmoset, a chimpanzee, or a baboon). The natural antibody may contain naturally occurring mutations. A number of IgG allotype sequences due to genetic polymorphisms are described in "Sequences of proteins of immunological interest", NIH Publication No. 91-3242, and any of them may be used in the present invention. In particular, for human IgG1, the amino acid sequence at positions 356 to 358 (EU numbering) may be either DEL or EEM. Preferred examples of the parent Fc region include Fc regions derived from the heavy chain constant regions of human IgG1 (SEQ ID NO: 58), human IgG2 (SEQ ID NO: 59), human IgG3 (SEQ ID NO: 60) and human IgG4 (SEQ ID NO: 61). Another preferred example of the parent Fc region is an Fc region derived from the heavy chain constant region SG1 (SEQ ID NO: 62). Furthermore, the parent Fc region may be an Fc region prepared by adding amino acid modifications other than those described herein to an Fc region derived from a natural antibody.

[0016] Furthermore, amino acid modifications performed for other purposes on the antibodies of the present invention may be combined with the antibodies used in the present invention. For example, amino acid substitutions that enhance FcRn binding activity (Hinton et al., J. Immunol. 176(1):346-356(2006); Dall'Acqua et al., J. Biol. Chem. 281(33):23514-23524(2006); Petkova et al., Intl. Immunol. 18(12):1759-1769(2006); Zalevsky et al., Nat. Biotechnol. 28(2):157-159(2010); WO2006 / 019447; WO2006 / 053301; and WO2009 / 086320) and amino acid substitutions to improve antibody heterogeneity or stability (WO2009 / 041613) may be added. Alternatively, amino acid modifications applied to polypeptides having the property of promoting antigen clearance as described in WO2011 / 122011, WO2012 / 132067, WO2013 / 046704, or WO2013 / 180201, polypeptides having the property of binding specifically to target tissues as described in WO2013 / 180200, or polypeptides having the property of repeatedly binding to multiple antigen molecules as described in WO2009 / 125825, WO2012 / 073992, or WO2013 / 047752 may be combined with the antibodies used in the present invention. Alternatively, amino acid modifications disclosed in EP1752471 and EP1772465 may be combined in the antibodies used in the present invention in order to confer binding ability to other antigens. Alternatively, the antibody used in the present invention may be combined with amino acid modifications that lower the pI of the constant region (WO2012 / 016227) for the purpose of increasing plasma retention, or with amino acid modifications that increase the pI of the constant region (WO2014 / 145159) for the purpose of promoting cellular uptake.Alternatively, amino acid modifications that increase the pI of the constant region (Patent Applications Nos. 2015-021371 and 2015-185254) may be combined to promote elimination of the target molecule from plasma.

[0017] In the present invention, the amino acid modification means any substitution, deletion, addition, insertion, and modification, or a combination thereof. In the present invention, the amino acid modification can be referred to as an amino acid mutation.

[0018] The antibody used in the present invention is more preferably an IgG antibody further comprising a substitution of one or more amino acid residues selected from among M428L, N434A, Y436T, Q438R, and S440E in the CH3 region, and more preferably an IgG antibody comprising a substitution of two or more amino acid residues selected from among M428L, N434A, Y436T, Q438R, and S440E in the CH3 region. Further preferred examples include an IgG antibody whose CH3 region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6 to 11, and an IgG antibody whose heavy chain constant region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 12 to 57.

[0019] The antibody used in the present invention is generally not particularly limited as long as it binds to the desired antigen, and may be a polyclonal or monoclonal antibody.

[0020] The monoclonal antibodies used in the present invention include not only monoclonal antibodies derived from animals such as humans, mice, rats, hamsters, rabbits, sheep, camels, and monkeys, but also artificially modified recombinant antibodies such as chimeric antibodies, humanized antibodies, and bispecific antibodies.Furthermore, recombinant antibodies in which the constant region of an antibody has been artificially modified to modify the physical properties of the antibody molecule (specifically, modification of the isoelectric point (pI), modification of the affinity of Fc receptors, etc.) for the purpose of improving blood retention and pharmacokinetics are also included.

[0021] Furthermore, the immunoglobulin class of the antibody used in the present invention is not particularly limited, and may be IgG such as IgG1, IgG2, IgG3, IgG4, etc. Preferred IgG in the present invention are IgG1, IgG2, and IgG4, particularly when the Fc region is of human origin.

[0022] The antibodies used in the present invention may also be used as pharmaceutical compositions and may be administered by any conventional means, including parenteral, pulmonary, and nasal administration, and, if desired for localized treatment, intralesional administration. Parenteral administration includes intramuscular, intravenous, intraperitoneal, or subcutaneous administration.

[0023] When the antibody used in the present invention is used as a pharmaceutical composition, a product containing the pharmaceutical composition and equipment useful for treatment, prevention, and / or diagnosis is provided. The product includes a container and a label on the container or a package insert associated with the container. Preferred containers include, for example, bottles, vials, syringes, IV solution bags, and the like. The containers may be formed from a variety of materials such as glass and plastic, and silicone-free syringes and the like can also be used.

[0024] The above-mentioned antibodies used in the present invention can be prepared by methods well known to those skilled in the art. Hybridomas producing monoclonal antibodies can be prepared basically using known techniques as follows. That is, a desired antigen or cells expressing the desired antigen are used as a sensitizing antigen, which is immunized according to a conventional immunization method, the resulting immune cells are fused with known parent cells by a conventional cell fusion method, and monoclonal antibody-producing cells (hybridomas) are screened by a conventional screening method. Hybridomas can be prepared, for example, according to the method of Milstein et al. (Kohler, G. and Milstein, C., Methods Enzymol. (1981) 73: 3-46) or the like. When the antigen has low immunogenicity, it may be bound to a macromolecule having immunogenicity such as albumin and then immunized.

[0025] Alternatively, a recombinant antibody can be produced by cloning an antibody gene from a hybridoma, incorporating it into a suitable vector, and introducing it into a host using recombinant gene technology (see, for example, Carl, AK Borrebaeck, James, W. Larrick, THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990). Specifically, cDNA of the variable region (V region) of an antibody is synthesized from the mRNA of a hybridoma using reverse transcriptase. Once DNA encoding the V region of the desired antibody is obtained, it is linked to DNA encoding the desired antibody constant region (C region), and this is incorporated into an expression vector. Alternatively, DNA encoding the V region of an antibody may be incorporated into an expression vector containing DNA of the antibody C region. It is incorporated into the expression vector so that it is expressed under the control of an expression control region, such as an enhancer or promoter. Next, the host cell is transformed with this expression vector to express the antibody.

[0026] In the present invention, recombinant antibodies that have been artificially modified for the purpose of reducing heterologous antigenicity against humans, such as chimeric antibodies and humanized antibodies, can be used. These modified antibodies can be produced using known methods. Chimeric antibodies are antibodies that consist of the variable regions of the heavy and light chains of an antibody from a mammal other than human, such as a mouse, and the constant regions of the heavy and light chains of a human antibody, and can be obtained by linking DNA encoding the variable region of a mouse antibody to DNA encoding the constant region of a human antibody, incorporating this into an expression vector, and introducing the vector into a host for production.

[0027] A humanized antibody, also called a reshaped human antibody, is a product of transplanting the complementarity determining region (CDR) of a non-human mammal, such as a mouse antibody, into the complementarity determining region of a human antibody, and a general genetic recombination method for the antibody is also known. Specifically, a DNA sequence designed to link the CDR of a mouse antibody and the framework region (FR) of a human antibody is synthesized by PCR from several oligonucleotides prepared so as to have overlapping portions at the ends. The resulting DNA is linked to DNA encoding the constant region of a human antibody, which is then incorporated into an expression vector, which is then introduced into a host for production (see EP 239400 and WO 96 / 02576). The FR of the human antibody linked via the CDR is selected from one whose complementarity determining region forms a good antigen-binding site. If necessary, amino acids in the framework region of the variable region of the antibody may be replaced so that the complementarity determining regions of the reshaped human antibody form an appropriate antigen-binding site (Sato, K. et al., Cancer Res. (1993) 53, 851-856).

[0028] Techniques for substituting amino acids in antibodies to improve the activity, physical properties, pharmacokinetics, safety, etc. of the antibodies include, for example, the techniques described below, and the antibodies used in the present invention also include antibodies with such amino acid substitutions (including deletions and additions).

[0029] Technologies for making amino acid substitutions in the variable regions of IgG antibodies include humanization (Tsurushita N, Hinton PR, Kumar S., Design of humanized antibodies: from anti-Tac to Zenapax., Methods. 2005 May;36(1):69-83.), affinity maturation by amino acid substitution in the complementarity determining region (CDR) to enhance binding activity (Rajpal A, Beyaz N, Haber L, Cappuccilli G, Yee H, Bhatt RR, Takeuchi T, Lerner RA, Crea R., A general method for greatly improving the affinity of antibodies by using combinatorial libraries., Proc Natl Acad Sci US A. 2005 Jun 14;102(24):8466-71.), and improvement of physicochemical stability by amino acid substitution in the framework (FR) (Ewert S, Honegger A, Pluckthun A., Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering., Methods. 2004 Oct;34(2):184-99. Review) has been reported. In addition, a technique for enhancing antibody-dependent cellular cytotoxicity (ADCC) activity and complement-dependent cytotoxicity (CDC) activity is known as a technique for performing amino acid substitution in the Fc region of an IgG antibody (Kim SJ, Park Y, Hong HJ., Antibody engineering for the development of therapeutic antibodies., Mol Cells. 2005 Aug 31;20(1):17-29. Review).Furthermore, techniques for amino acid substitution in the Fc region that not only enhance such effector functions but also improve the blood half-life of antibodies have been reported (Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N., An engineered human IgG1 antibody with longer serum half-life., J Immunol. 2006 Jan 1;176(1):346-56., Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, Ober RJ, Ward ES., Increasing the serum persistence of an IgG fragment by random mutagenesis., Nat Biotechnol. 1997 Jul;15(7):637-40.). Furthermore, various amino acid substitution techniques in the constant region for the purpose of improving the physical properties of antibodies are also known (WO 09 / 41613).

[0030] Methods for obtaining human antibodies are also known. For example, human lymphocytes can be sensitized in vitro with a desired antigen or cells expressing the desired antigen, and the sensitized lymphocytes can be fused with human myeloma cells, such as U266, to obtain a desired human antibody having binding activity to the antigen (see JP-B-1-59878). Also, a desired human antibody can be obtained by immunizing a transgenic animal having a full repertoire of human antibody genes with an antigen (see WO 93 / 12227, WO 92 / 03918, WO 94 / 02602, WO 94 / 25585, WO 96 / 34096, WO 96 / 33735). Furthermore, a technique for obtaining a human antibody by panning using a human antibody library is also known. For example, the variable region of a human antibody can be expressed on the surface of a phage as a single chain antibody (scFv) by phage display, and a phage that binds to the antigen can be selected. By analyzing the genes of the selected phage, the DNA sequence encoding the variable region of the human antibody that binds to the antigen can be determined. Once the DNA sequence of the scFv that binds to the antigen is identified, an appropriate expression vector containing the sequence can be constructed to obtain a human antibody. These methods are already well known, and reference can be made to WO 92 / 01047, WO 92 / 20791, WO 93 / 06213, WO 93 / 11236, WO 93 / 19172, WO 95 / 01438, and WO 95 / 15388. The antibody used in the present invention also includes such a human antibody.

[0031] When an antibody gene is isolated and then introduced into a suitable host to produce an antibody, a suitable combination of a host and an expression vector can be used. When a eukaryotic cell is used as a host, an animal cell, a plant cell, or a fungal cell can be used. Known animal cells include (1) mammalian cells, such as CHO, COS, myeloma, BHK (baby hamster kidney), HeLa, and Vero, (2) amphibian cells, such as Xenopus oocytes, and (3) insect cells, such as sf9, sf21, and Tn5. Known plant cells include cells derived from the genus Nicotiana, such as Nicotiana tabacum, which can be cultured as callus. Known fungal cells include yeasts such as Saccharomyces, e.g., Saccharomyces cerevisiae, and filamentous fungi such as Aspergillus, e.g., Aspergillus niger. When using prokaryotic cells, there are production systems using bacterial cells. Known examples of bacterial cells include E. coli and Bacillus subtilis. Antibodies can be obtained by introducing the desired antibody gene into these cells by transformation and culturing the transformed cells in vitro.

[0032] Modified antibodies may also be used that are conjugated with various molecules such as polyethylene glycol (PEG) or cytotoxic drugs (Farmaco. 1999 Aug 30; 54(8): 497-516., Cancer J. 2008 May-Jun; 14(3): 154-69.). The antibodies used in the present invention also include these modified antibodies. Such modified antibodies can be obtained by chemically modifying the antibodies. These methods have already been established in this field.

[0033] Antibodies used in the present invention include, but are not limited to, anti-tissue factor antibodies, anti-IL-6 receptor antibodies, anti-IL-6 antibodies, anti-HM1.24 antigen monoclonal antibodies, anti-parathyroid hormone-related peptide antibodies (anti-PTHrP antibodies), anti-glypican-3 antibodies, anti-ganglioside GM3 antibodies, anti-TPO receptor agonist antibodies, coagulation factor VIII functional substitute antibodies, anti-IL31 receptor antibodies, anti-HLA antibodies, anti-AXL antibodies, anti-CXCR4 antibodies, anti-NR10 antibodies, and bispecific antibodies that recognize both Factor IX(a) and Factor X.

[0034] The antibody used in the present invention preferably has a pI value of 4.0 to 10.0, more preferably 5.0 to 9.5, and even more preferably 6.0 to 9.0. These pI values ​​are higher than the pI value of the IgG antibody before the amino acid modification. The isoelectric point of the IgG antibody can be evaluated by known analytical methods such as isoelectric focusing.

[0035] The protein A modified ligand of the present invention preferably binds to the Fc region of an IgG antibody to be purified in the present invention in an amount 5-fold or more, and more preferably 10-fold or more, of the IgG antibody bound to the unmodified protein A. The method for measuring the binding amount referred to here is not particularly limited, and examples thereof include the method for measuring the dynamic binding capacity described in the Examples of the present application.

[0036] Specific examples of commonly used Protein A columns include HiTrap MabSelect SuRe (manufactured by GE Healthcare, product name), Amsphere A3 (manufactured by JSR Life Sciences, registered trademark), MiniChrom Column Eshmuno A (manufactured by Merck Millipore, registered trademark), MabSpeed ​​rP202 (manufactured by Mitsubishi Chemical, registered trademark), and KanCap Pre-packaged Column (manufactured by Kaneka, product name).

[0037] The Protein A affinity column used in the present invention is a column having a modified C domain or a modified Z domain in which one or more of the original lysine residues at positions 4, 7, and 35 are replaced with amino acid residues other than lysine, and further comprising Q311R and P An affinity column is used that includes a carrier on which a modified protein A ligand is immobilized, the modified immunoglobulin-binding domain having binding ability to IgG antibodies, which includes a substitution of the amino acid residue at 343R, or a multimer of such modified immunoglobulin-binding domain. This modified protein A ligand is a modified protein A C domain (SEQ ID NO: 1) in which the glycine residue at position 29 in the amino acid sequence of the C domain of protein A is substituted with an alanine residue, or a modified protein A Z domain (SEQ ID NO: 2) in which one or more lysine residues at positions 4, 7, and 35 are substituted with other amino acid residues, and is characterized in that, when immobilized on an insoluble carrier via its own amino group, the orientation for maintaining affinity for immunoglobulins is improved compared to the molecule before modification.

[0038] In the present invention, the term "immunoglobulin-binding domain" refers to a functional unit of a polypeptide having immunoglobulin-binding activity alone, and the term "modified immunoglobulin-binding domain" refers to an original immunoglobulin-binding domain that has been modified. The term "ligand" refers to a molecule that has the property of binding to a specific molecule by specific affinity, and in the present invention refers to an immunoglobulin-binding protein that can selectively bind to immunoglobulins. The term "Protein A modified ligand" refers to an immunoglobulin-binding protein that contains a modified immunoglobulin-binding domain obtained by modifying the binding domain of Protein A. Here, in the present specification, the "modified immunoglobulin-binding domain" and the "Protein A modified ligand" are collectively referred to as "modified proteins".

[0039] The modified immunoglobulin-binding domain used in the present invention may further comprise an amino acid sequence in which one or more of the lysine residues at positions 4, 7 and 35 of the modified C domain (SEQ ID NO: 1) have been substituted with other amino acid residues, or in which the Z domain (SEQ ID NO: 2) has been substituted with other amino acid residues. For example, it is desirable that two or more, preferably three, of the lysine residues at positions 4, 7 and 35 have been substituted with other amino acid residues.

[0040] The type of amino acid after substitution at one or more of positions 4, 7, and 35 of the C domain variant (SEQ ID NO: 1) or the Z domain (SEQ ID NO: 2) is not particularly limited, but is preferably alanine, glutamine, asparagine, valine, serine, threonine, histidine, tyrosine, or arginine, and more preferably alanine, threonine, or arginine.

[0041] More specifically, the type of amino acid after substitution at position 4 of the C domain variant (sequence number 1) or the Z domain (sequence number 2) is preferably glutamic acid, isoleucine, arginine, alanine, valine, serine, threonine, or histidine, and more preferably alanine.

[0042] Furthermore, the type of amino acid after substitution at position 7 of the C domain variant (sequence number 1) or the Z domain (sequence number 2) is preferably tyrosine, phenylalanine, glutamine, leucine, isoleucine, proline, threonine, alanine, valine, serine, arginine, or histidine, and more preferably threonine.

[0043] Furthermore, the type of amino acid after substitution at position 35 of the variant C domain (SEQ ID NO: 1) or Z domain (SEQ ID NO: 2) is preferably arginine, glutamine, asparagine, or tyrosine, more preferably arginine.

[0044] In addition, the C domain variant (SEQ ID NO: 1) or the Z domain (SEQ ID NO: 2) is Q311R and PIn addition to the above modifications, one or several amino acids may be substituted, so long as the antibody has the ability to bind to an IgG antibody containing the substitution of the amino acid residue at 343R. In particular, in the modified C domain (SEQ ID NO: 1) or Z domain (SEQ ID NO: 2), it is preferable that the number of lysines contained as constituent amino acids is small, and in addition to the above modifications, it is desirable that 1 to 4, preferably 3 or 4, more preferably 4 of the original lysine residues at positions 42, 49, 50, and 58 are substituted with amino acid residues other than lysine.

[0045] The type of amino acid after substitution at one or more of positions 42, 49, 50, and 58 of the C domain variant (SEQ ID NO: 1) or the Z domain (SEQ ID NO: 2) is not particularly limited, but is preferably alanine, glutamine, asparagine, valine, serine, threonine, histidine, tyrosine, or arginine, and more preferably alanine or arginine.

[0046] More specifically, when substituting the native lysine residue at position 42 of the C domain variant (SEQ ID NO: 1) or Z domain (SEQ ID NO: 2) with another amino acid residue, the type of amino acid after substitution is preferably alanine, valine, serine, threonine, or histidine, and more preferably alanine.

[0047] Furthermore, when substituting the native lysine residue at position 49 of the C domain variant (SEQ ID NO: 1) or Z domain (SEQ ID NO: 2) with another amino acid residue, the type of amino acid after substitution is preferably arginine, glutamine, asparagine, or tyrosine, and more preferably arginine.

[0048] Furthermore, when substituting the native lysine residue at position 50 of the C domain variant (sequence number 1) or Z domain (sequence number 2) with another amino acid residue, the type of amino acid after substitution is preferably arginine, glutamine, asparagine, or tyrosine, and more preferably arginine.

[0049] Furthermore, when substituting the native lysine residue at position 58 of the C domain variant (SEQ ID NO: 1) or Z domain (SEQ ID NO: 2) with another amino acid residue, the type of amino acid after substitution is preferably arginine, glutamine, asparagine, or tyrosine, and more preferably arginine.

[0050] In addition to the above modifications, the modified immunoglobulin-binding domain of the present invention may have the aspartic acid residue at position 37 of the modified C domain (SEQ ID NO: 1) or the Z domain (SEQ ID NO: 2) substituted with an amino acid residue other than aspartic acid, which improves the chemical stability under acidic pH conditions compared to the unmodified molecule.

[0051] When replacing the original aspartic acid residue at position 37 of the C domain variant (SEQ ID NO: 1) or Z domain (SEQ ID NO: 2) with another amino acid residue, the type of amino acid to be substituted is not particularly limited, but is preferably alanine, glutamic acid, serine, threonine, leucine, or isoleucine.

[0052] Suitable examples of the amino acid sequence of the modified immunoglobulin-binding domain used in the present invention include the amino acid sequence shown in SEQ ID NO: 3 or 5. The amino acid sequence shown in SEQ ID NO: 3 is an amino acid sequence in which the 4th position, the 7th position, and the 35th position of the amino acid sequence shown in SEQ ID NO: 1 are substituted with an alanine residue, a 7th residue, an arginine residue, an alanine residue, a 42nd residue, an arginine residue, a 50th residue, and an 58th residue, in the amino acid sequence shown in SEQ ID NO: 1. In addition to the above, the following amino acid sequences are also suitable examples of amino acid sequences of the modified immunoglobulin-binding domain of the present invention: [1] A substitution of lysine at position 35 with glutamine or arginine in a C domain variant defined in SEQ ID NO:1; [2] A modified C domain as defined in SEQ ID NO:1, in which the amino acid residues at positions 40, 43, 46, and 53 are replaced with lysine, and the lysine at position 35 is replaced with arginine or valine. [3] In the amino acid sequence of [2], further comprising substituting lysine at position 7 with tyrosine, phenylalanine, threonine, arginine, glutamine, valine, leucine, isoleucine, histidine, alanine, or proline; [4] The amino acid sequence of [2] or [3] further comprising a substitution of alanine for lysine at position 4; [5] A C domain variant defined in SEQ ID NO:1, in which the amino acid residues at positions 40, 43, 46, and 53 are substituted with lysine, and the lysine at position 4 is substituted with valine, isoleucine, glutamic acid, or arginine; [6] a C domain variant defined in SEQ ID NO:1, in which the lysine at position 42 is replaced with alanine, the lysines at positions 49, 50, and 58 are replaced with arginine, and the lysine at position 4 is replaced with valine, isoleucine, glutamic acid, or arginine; [7] In the amino acid sequence of [5] or [6], the lysine at positions 7 and 35 is additionally replaced with arginine.

[0053] When the protein A modified ligand is a multimer having an immunoglobulin-binding domain as a constituent unit, it is sufficient that the multimer contains one or more immunoglobulin-binding domains containing the above-mentioned modification. The number of immunoglobulin-binding domain units contained in the multimer is, for example, 2 to 10, preferably 2 to 8, more preferably 4 to 7, and even more preferably 6. The multimer may contain an immunoglobulin-binding domain that does not contain the above-mentioned modification, as long as the multimer contains one or more immunoglobulin-binding domains containing the above-mentioned modification. In the multimer, the proportion of the immunoglobulin-binding domains containing the above-mentioned modification to the total number of immunoglobulin-binding domains contained as constituent units is preferably 50% or more, and more preferably 100% (i.e., all of the immunoglobulin-binding domains contained as constituent units have the above-mentioned modification).

[0054] When the protein A modified ligand is a multimer having immunoglobulin-binding domains as its constituent units, the immunoglobulin-binding domain located at the first and / or second position from the N-terminus or C-terminus of the multimer may be substituted with an amino acid residue capable of covalently binding to a carrier (e.g., a lysine residue) in order to facilitate immobilization to a carrier. For example, in the modified C domain (SEQ ID NO: 1) or Z domain (SEQ ID NO: 2) located at the first and / or second position from the N-terminus or C-terminus of the multimer, at least one, preferably 2 to 6, more preferably 3 or 4, and even more preferably 4 of the original amino acid residues at positions 40, 43, 46, 53, 54, and 56 are substituted with lysine residues, thereby facilitating immobilization to a carrier.

[0055] Furthermore, the immunoglobulin-binding domain located at the first and / or second position from the N-terminus or C-terminus of the multimer may be a C domain variant (SEQ ID NO: 1) or a Z domain (SEQ ID NO: 2) in which one or more lysine residues at positions 4, 7, and 35 are not substituted with other amino acid residues, but one or more of these lysine residues may be substituted with other amino acid residues. An example of an immunoglobulin-binding domain located at the first and / or second position from the N-terminus or C-terminus of the multimer is the amino acid sequence shown in SEQ ID NO: 4. The amino acid sequence shown in SEQ ID NO: 4 is an amino acid sequence in which the amino acid sequence shown in SEQ ID NO: 1 is substituted with an alanine residue at position 4, a threonine residue at position 7, an arginine residue at position 35, a lysine residue at position 40, a lysine residue at position 43, a lysine residue at position 46, and a lysine residue at position 53.

[0056] An example of the multimer is the modified protein A ligand represented by formula (1) below. (R1) n -(R2) m , or (R2) m -(R1) n (1)

[0057] In formula (1), the left end is the N-terminus and the right end is the C-terminus.

[0058] In formula (1), n ​​is an integer of 1 to 9, preferably an integer of 1 to 7, more preferably an integer of 3 to 6, and even more preferably 5. m is an integer of 1 or 2, and preferably 1. The total number of domains, n+m, is 2 to 10, preferably 2 to 8, more preferably 4 to 7, and even more preferably 6.

[0059] In formula (1), (R1) is a modified immunoglobulin-binding domain in which any one or more (preferably all) of positions 4, 7, and 35 of a modified C domain (SEQ ID NO: 1) or a Z domain (SEQ ID NO: 2) have been substituted with amino acid residues other than lysine. In addition to the substitutions at positions 4, 7, and 35, (R1) preferably has any one or more (preferably all) of positions 42, 49, 50, and 58 substituted with amino acid residues other than lysine. All of the n (R1)s may be the same amino acid sequence, or may be different amino acid sequences from one another.

[0060] In formula (1), (R2) is a modified C domain (SEQ ID NO: 1) or an immunoglobulin-binding domain in which any one or more (preferably all) of positions 40, 43, 46, 53, 54, and 56 of the Z domain (SEQ ID NO: 2) have been substituted with lysine residues. In addition to the substitution at any one or more of positions 40, 43, 46, 53, 54, and 56, (R2) preferably has any one or more (preferably all) of positions 4, 7, and 35 substituted with amino acid residues other than lysine. When m is 2, the two (R2) may all be the same amino acid sequence, or may be different sequences from each other.

[0061] A preferred example of the modified protein A ligand represented by formula (1) is a modified immunoglobulin-binding domain in which n is 5; m is 1; (R1) is an amino acid sequence shown in SEQ ID NO: 5 (an amino acid sequence in which position 4 of SEQ ID NO: 1 is substituted with an alanine residue, position 7 with a threonine residue, position 35 with an arginine residue, position 42 with an alanine residue, position 49 with an arginine residue, position 50 with an arginine residue, and position 58 with an arginine residue); and (R2) is an modified immunoglobulin-binding domain in which position 4 of SEQ ID NO: 1 is substituted with an alanine residue, position 7 with a threonine residue, position 35 with an arginine residue, position 40 with a lysine residue, position 43 with a lysine residue, position 46 with a lysine residue, and position 53 with a lysine residue).

[0062] The protein A modified protein of the present invention can be produced by utilizing known gene recombination techniques, for example, as described in Current Protocols in Molecular Biology by Frederick M. Ausbel et al. That is, an expression vector containing a nucleic acid sequence encoding the modified protein of interest is transformed into a host such as Escherichia coli, and the cells are cultured in an appropriate liquid medium, whereby the protein A modified protein can be obtained in large quantities and economically from the cultured cells. Specifically, since one immunoglobulin-binding domain of protein A is a small protein consisting of about 60 amino acids, for example, a DNA encoding a desired amino acid sequence can be divided and synthesized into synthetic oligonucleotides consisting of several tens of bases, which are then linked by a ligation reaction using DNA ligase and inserted into a plasmid vector to obtain the desired expression vector.

[0063] In this case, it is common for those skilled in the art to adopt a nucleic acid sequence using optimal codons for E. coli in order to efficiently express the protein in E. coli. The amino acid sequence of the immunoglobulin-binding domain before modification may be that of any domain of protein A, but it is preferable to use the C domain, which has many lysine residues at positions 39 and after, among the five domains that are originally present. Alternatively, the sequence of the Z domain, which has a long history of use as an affinity ligand for immunoglobulins, may be used, but it is most preferable to adopt the sequence of a modified C domain (shown in SEQ ID NO: 1 in the sequence listing) in which the glycine residue at position 29 has been replaced with an alanine residue (Nilsson B. et. Al, Protein Engineering, 1(2), pp.107-113), which is already known to increase chemical stability. Mutations in the DNA sequence to achieve the desired amino acid substitution can be easily introduced into the intended site using the overlap extension method, in which a synthetic oligo DNA incorporating a mismatched base pair is used as a primer for polymerase chain reaction using the clone DNA before modification as a template, or the cassette mutagenesis method. Furthermore, when using an immunoglobulin-binding protein derived from Protein A as a ligand for immunoglobulin affinity chromatography, a multimeric protein in which two or more, preferably about four, immunoglobulin-binding domains are linked has been conventionally produced and used. It is preferable that the immunoglobulin-binding protein obtained by the present invention is also produced and used as a multimeric protein in which two or more, preferably 2 to 10, more preferably 4 to 7, and even more preferably 6 immunoglobulin-binding domains are linked. A cDNA encoding such a multimeric protein can be easily produced by linking the intended number of cDNAs encoding one immunoglobulin-binding domain in series. By inserting the cDNA thus produced into an appropriate expression plasmid and using it, it is possible to easily produce a multimeric protein in which two or more immunoglobulin-binding domain units are linked.

[0064] As an expression vector into which a nucleic acid sequence encoding a modified protein of the present invention is inserted, any vector capable of replicating in a host cell, such as a plasmid, phage, or virus, can be used. For example, commercially available expression vectors include pQE-based vectors (Qiagen), pDR540, pRIT2T (GE Healthcare Biosciences), and pET-based vectors (Merck Ltd.). It is preferable to select and use an appropriate combination of an expression vector with a host cell. For example, when Escherichia coli is used as a host cell, a combination of a pET-based vector and a BL21(DE3) Escherichia coli strain or a combination of a pDR540 vector and a JM109 Escherichia coli strain is preferred.

[0065] The modified protein of the present invention can be recovered in a soluble fraction by collecting the cultured cells by centrifugation or the like and disrupting them by treatment using ultrasonic waves, a French press, etc. The modified protein can be purified by appropriately combining known separation and purification techniques. Specific examples of such purification techniques include separation techniques such as salting out, dialysis, and ultrafiltration, as well as hydrophobic chromatography, gel filtration chromatography, ion exchange chromatography, affinity chromatography, and reverse phase chromatography.

[0066] Examples of insoluble carriers to which the modified protein of the present invention is bound as an affinity ligand for immunoglobulin include natural polymeric materials such as chitosan and dextran, and synthetic polymers such as vinyl polymers, highly cross-linked agarose, and polyimides. Alternatively, inorganic carriers such as silica may be used. Usually, the ligand protein is immobilized on the carrier by a coupling agent such as cyanogen bromide, epichlorohydrin, N-hydroxysuccinimide, tosyl / tresyl chloride, carbodiimide, glutaraldehyde, or hydrazine, or a carboxyl or thiol activated carrier. Such coupling reactions are well known in the art and have been widely described in the literature (e.g., Jansson, JC and Ryden, L., "Protein purification", 2nd edition, pp. 375-442, ISBN 0-471-18626-0). The ligand protein of the present invention is characterized in that it is bound to a carrier via a plurality of amino groups arranged so that the spatial orientation of the ligand can be controlled, and for immobilizing the protein, a carrier having an active group capable of reacting with the amino group of the protein to form a covalent bond, such as a tresyl group, an epoxy group, a carboxyl group, or a formyl group, can be used. Commercially available carriers include Toyopearl AF-Tresyl-650, Toyopearl AF-Epoxy-650, Toyopearl AF-Carboxy-650, Toyopearl AF-Formyl-650 (all from Tosoh Corporation), NHS-activated Sepharose, cyanogen bromide-activated Sepharose, and epoxy-activated Sepharose (all from GE Healthcare Biosciences, Inc.).

[0067] The Protein A affinity column used in the present invention may have the above-mentioned modified Protein A ligand immobilized thereon by any means, and for example, it can be immobilized by the following means. (1) A method in which one to six of the amino acid residues at positions 40, 43, 46, 53, 54, and 56 in a modified C domain or Z domain of Protein A are additionally substituted with lysine residues, and the modified C domain or Z domain is immobilized on a carrier via the substituted lysine residues; (2) A method in which cysteine ​​is introduced at the C-terminus of Protein A and immobilized on a carrier via a disulfide bond or a thioether bond; (3) A method of immobilizing the thiol group on an amino group-containing solid support by cyanating the thiol group; (4) A method for immobilizing a multimer of a modified immunoglobulin binding domain having cysteine ​​residues to an amino group-containing support using 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) as a crosslinking agent; and (5) A method of immobilizing to a carrier via multiple (e.g., five) lysine residues added to the C-terminus of a modified immunoglobulin-binding domain in which the lysine residues at positions 42, 49, 50, and 58 of a modified C domain of protein A have been replaced with amino acids other than lysine residues, or a modified immunoglobulin-binding domain in which the lysine residues at positions 49, 50, and 58 of the Z domain have been replaced with amino acids other than lysine. The above-mentioned immobilization method can be carried out by a commonly used method.

[0068] Preferably, this method involves additionally substituting one to six of the amino acid residues at positions 40, 43, 46, 53, 54, and 56 in a modified C domain or Z domain of protein A with lysine residues, and immobilizing the protein A on a carrier via the substituted lysine residues.

[0069] A specific example of the Protein A affinity column used in the present invention is AF-rProtein A HC-650F (manufactured by Tosoh Corporation), which is an affinity resin in which an Fc-binding ligand (recombinant modified Protein A) is bound to a synthetic polymer support TOYOPEARL HW-56.

[0070] The carrier with the immobilized modified protein A ligand prepared as described above can be packed into a column to form an affinity column (step a). Next, a composition containing an IgG antibody having an amino acid sequence modified in the CH2 or CH3 region is loaded onto the prepared affinity column (step b). In the present invention, the composition containing an IgG antibody refers to, for example, a culture of IgG antibody-expressing cells or its supernatant. In general, a culture is a complex composition composed of various components such as metabolic products of cells as well as various nutrients necessary for cultivation. In order to highly purify the desired IgG antibody from the culture to a purity required for a pharmaceutical raw material, it is necessary to determine purification conditions suitable for the desired IgG antibody. According to the present invention, the purification of an IgG antibody containing substitutions of amino acid residues Q311R and P343R in the CH2 or CH3 region can be performed by using the C domain of protein A. Modified form Alternatively, it has been revealed that a variant having a modification in which one or more of the original lysine residues at positions 4, 7, or 35 in the Z domain are replaced with an amino acid residue other than lysine and having the ability to bind to the IgG antibody is a suitable purification tool.

[0071] The composition containing the IgG antibody can be pretreated by filtration, centrifugation, or the like before loading it onto the affinity column. The composition containing the IgG antibody can be loaded onto the affinity column at an appropriate pressure and flow rate according to the size and capacity of the column, or the size of the carrier, using a general liquid chromatography system. It is desirable that the amount of the IgG antibody composition loaded onto the affinity column is approximately the same as the IgG antibody binding capacity of the affinity column. For example, the binding capacity of the IgG antibody can be known by monitoring the concentration of the IgG antibody flowing out from the affinity column to which the composition is loaded. That is, when the level of the IgG antibody flowing out from the affinity column becomes the same as the IgG antibody concentration in the loaded composition, it can be determined that the IgG antibody has approached the IgG antibody binding capacity of the affinity column. Then, by eluting the IgG antibody from the affinity column (step c), efficient purification of the IgG antibody can be expected.

[0072] The purification method of the present invention may additionally comprise a step of washing the affinity column with a washing solution prior to step (c).

[0073] The cleaning solution is not particularly limited, but may be a combination of a buffer and a salt, the buffer containing at least one selected from the group consisting of phosphoric acid, acetic acid, citric acid, glycine, and trishydroxymethylaminomethane, and the salt containing at least one selected from the group consisting of arginine, sodium chloride, and sodium sulfate.

[0074] After washing the affinity column as necessary, the IgG antibody adsorbed on the affinity column can be eluted to recover the purified IgG antibody (step c). The method for eluting the IgG antibody adsorbed on the protein A modified ligand can be appropriately selected from known conditions. For example, a solution containing at least one selected from the group consisting of hydrochloric acid, acetic acid, citric acid, arginine, glycine, and phosphoric acid can be used. The concentration of the solution for eluting the IgG antibody from the affinity column can be appropriately adjusted depending on the purpose, and can be, for example, 20 to 500 mM, usually 50 to 200 mM for acetic acid, and 1 to 5 mM for hydrochloric acid. During elution of the IgG antibody from the affinity column, the elution of the IgG antibody can also be tracked by monitoring the protein concentration of the eluate.

[0075] After step (c), the recovered IgG antibody can be further purified, if necessary. For example, the purification method of the present invention may additionally include a step of purifying the IgG antibody by at least one chromatography selected from the group consisting of cation exchange chromatography, anion exchange chromatography, hydrophobic interaction chromatography, multimode chromatography, and hydroxyapatite chromatography. Through the above-mentioned steps, in a preferred embodiment of the present invention, an IgG antibody can be isolated from inside or outside a host cell (such as a medium) and purified as a substantially pure and homogeneous IgG antibody. That is, the present invention provides a method for producing a purified IgG antibody, comprising the following steps: (i) providing a composition containing an IgG antibody comprising amino acid residue substitutions Q311R and P343R; (ii) preparing an affinity column comprising a carrier on which a modified protein A ligand is immobilized, the modified immunoglobulin-binding domain comprising a modification in which any one or more of the original lysine residues at positions 4, 7 and 35 of the modified Staphylococcus protein A C domain defined in SEQ ID NO:1 or the Z domain defined in SEQ ID NO:2 are substituted with amino acid residues other than lysine, or a multimer of such modified immunoglobulin-binding domain; (iii) loading the composition containing the IgG antibody onto the affinity column of step (ii); and (iv) eluting and recovering the IgG antibody from the affinity column loaded with the composition containing the IgG antibody in step (iii). The present invention also encompasses IgG antibodies highly purified using these purification methods.

[0076] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these. EXAMPLES

[0077] In order to improve the pharmacokinetics of Antibody A, the isoelectric point (pI) has been increased and its affinity for Fc receptor IIb (FcRIIb) and neonatal Fc receptor (FcRn) has been enhanced by antibody engineering techniques, and the amino acid residues Q311R and P343R in the CH2 and CH3 regions have been substituted to produce an Fc region of SEQ ID NO: 10. However, as a result, Antibody A has a weakened binding affinity for Protein A. In other words, the improved pharmacokinetics of Antibody A has increased its usefulness as a pharmaceutical product, but at the same time, it has become subject to new manufacturing problems.

[0078] The binding affinity of antibodies to Protein A is often utilized in the purification process (affinity purification). Specifically, the process of adsorbing an antibody to a column immobilized with Protein A, washing, and then eluting and recovering the antibody is widely used as an antibody purification method. Protein A binds to the Fc region of antibodies, so it is used to purify a wide range of antibodies regardless of the antigen specificity of the antibody. Furthermore, various Protein A columns with modified Protein A immobilization methods, resins, or Protein A itself are commercially available.

[0079] To find a protein A immobilized resin applicable to affinity purification of antibody A, the affinity of the antibody to the following commercially available protein A immobilized resins was compared: HiTrap MabSelect SuRe (product name, manufactured by GE Healthcare); ToyoScreen AF-rProtein A HC-650F (manufactured by Tosoh, product name); Amsphere A3 (manufactured by JSR Life Sciences, registered trademark); MiniChrom Column Eshmuno A (Merck Millipore, registered trademark); MabSpeed ​​rP202 (manufactured by Mitsubishi Chemical, registered trademark); KanCap Pre-packaged Column (Kaneka product name).

[0080] (1) Dynamic binding capacity (DBC) of antibody A in each column Purified antibody A was dissolved in equilibration buffer and loaded onto a column packed with each Protein A immobilized resin. The protein concentration of the buffer eluted from the column was monitored by ultraviolet light to identify the 5% elution point, and the DBC per 1 L of resin was determined by the following formula. The 5% elution point means the amount of protein loaded onto the column at the point when the protein concentration of the eluate exceeded 5% of the protein concentration of the antibody solution loaded onto the column: Antibody A concentration (g / L) x volume loaded (5% breakthrough point) (L) DBC= ―――――――――――――――――――――――――――――― Column capacity (L) Similarly, for comparison, the DBC of each column was also determined for a humanized antibody that did not contain any modifications in the Fc region of human IgG1.

[0081] (2) Dynamic binding capacity; DBC [Table 1]

[0082] AF-rProtein A HC-650F, which bound a large amount of antibody A, showed high DBCs of 46.6 and 45.2 when evaluated using two resins from different production lots. The second highest DBC after AF-rProtein A HC-650F was Amsphere A3, at 13.6. The DBCs of the other resins were quite low, ranging from 1.6 to 6.4. On the other hand, for antibodies with unmodified Fc regions, the DBCs of each resin were 20 to 70, as shown in Figure 1, which were sufficient for antibody purification.

[0083] AF-rProtein A HC-650F (manufactured by Tosoh Corporation) is an affinity resin in which an Fc-binding ligand (a recombinant modified protein A) is bound to a synthetic polymer support TOYOPEARL HW-65. The ligand bound to AF-rProtein A HC-650F has the structure shown in formula (1') below: (R1)5-(R2)1(1') In the above formula (1'), the left end is the N-terminus and the right end is the C-terminus. In the above formula (1'), (R2) is a modified immunoglobulin-binding domain (SEQ ID NO: 4) in which the amino acid sequence of the modified C domain (SEQ ID NO: 1) in which a part of the amino acid sequence of the C domain of the immunoglobulin-binding domain constituting protein A derived from Staphylococcus aureus is substituted (G29A) with an alanine residue at position 4, a threonine residue at position 7, an arginine residue at position 35, a lysine residue at position 40, a lysine residue at position 43, a lysine residue at position 46, and a lysine residue at position 53. The five (R1)s arranged on the N-terminus side are modified immunoglobulin-binding domains (SEQ ID NO: 5) consisting of an amino acid sequence in which, in addition to the sequence in which position 4 of the modified C domain is substituted with an alanine residue, position 7 with a threonine residue, and position 35 with an arginine residue, positions 42, 49, 50, and 58 are substituted with an arginine residue. That is, formula (1') is a ligand consisting of an amino acid sequence in which, from the N-terminus side, five amino acids of the amino acid sequence shown in SEQ ID NO: 5 and one amino acid sequence shown in SEQ ID NO: 4 are linked. In the above variant, the modified immunoglobulin-binding domain is made into a hexamer, thereby further strengthening the binding to the Fc region. AF-rProtein A HC-650F is an affinity resin that has significantly improved Fc binding ability and is also alkaline-resistant due to the use of a variant having the above structure. The affinity resins used in this comparative test are all products in which the structure of Protein A itself and its binding mode with the carrier have been optimized, and which have enhanced binding affinity with the Fc region, alkaline resistance, etc. When the Fc region is not modified, all of them show excellent binding affinity with antibodies, but when the Fc region is modified, it became clear that the affinity resin brings about a large difference in binding affinity with antibodies. EXAMPLES

[0084] To evaluate the binding ability of the ligand to the pI-modified antibody containing the substitutions of amino acid residues Q311R and P343R, the KD values ​​of AF-rProtein A HC-650F and MabSelect SuRe used in Example 1 were measured using the BLItz (registered trademark) (ForteBio) evaluation system. The ligand of AF-rProtein A HC-650F (structure shown in formula (1')) and the ligand of MabSelect SuRe were each labeled with biotin (Lys:Biotin = 1:1) and then immobilized on the surface of a sensor chip. After equilibration with PBS solution, a solution containing the antibody was diluted with PBS (+0.1% BSA) buffer and added, and then PBS (+BSA) was added to measure the dissociation reaction. In addition to antibody A, tocilizumab (hPM-1 or MRA: see International Patent Application Publication No. WO92-19759), a humanized anti-interleukin 6 (IL-6) receptor antibody, was used as a comparative example. Unlike antibody A, tocilizumab does not contain substitutions of amino acid residues Q311R and P343R for pI modification (non-pI modified antibody). The test results are summarized in Figure 2 and Table 2. For the ligand of AF-rProtein A HC-650F, tocilizumab was K D The value is 1.55 x 10 -9 Antibody A bound to K. D The value is 184 x 10 -9 Although the affinity was weaker than that of tocilizumab, binding was observed with M. On the other hand, for the ligand of MabSelect SuRe, tocilizumab had a higher affinity than K DThe value is 8.11 x 10 -9 Binding was observed with antibody M, but no binding was observed with antibody A.

[0085] [Table 2] EXAMPLES

[0086] To evaluate the relationship between substitution of amino acid residues in the ligand and binding strength to the pI-modified antibody, the KD value of antibody A was measured for a ligand monomer in which mutations were introduced at positions 4, 7, and 35 of the C domain variant (sequence number 1) using a method similar to that used in Example 2 (except that Lys:Biotin was changed to 12:1). The results in Table 3 show that the affinity to antibody A was increased by substituting the lysine residue (K) at position 35 of the modified C domain with a glutamine residue (Q) or arginine residue (R).

[0087] [Table 3] *Denotes no substitutions for the C domain variants (position 4: K, position 7: K, position 35: K).

[0088] In addition, for a ligand monomer in which the amino acid residues at positions 40, 43, 46, and 53 of the C domain variant were replaced with lysine residues (K) (hereinafter referred to as "ligand monomer of R2' structure"), different mutations were introduced at positions 4, 7, and 35, and the KD value of antibody A was measured using a method similar to that of Example 2 (except that Lys:Biotin was changed to 12:1). From the results in Table 4, it was found that the affinity to antibody A was increased by substituting the lysine residue (K) at position 35 of the ligand monomer having the R2' structure with an arginine residue (R) or a valine residue (V), particularly with an arginine residue (R). In addition to the substitution at position 35, it was also found that the affinity to antibody A was increased by substituting the lysine residue (K) at position 7 with any of a tyrosine residue (Y), a phenylalanine residue (F), a threonine residue (T), an arginine residue (R), a glutamine residue (Q), a valine residue (V), a leucine residue (L), an isoleucine residue (I), a histidine residue (H), an alanine residue (A), or a proline residue (P), particularly with a tyrosine residue (Y) or a phenylalanine residue (F).

[0089] [Table 4] *Denotes no substitutions in the C domain variants (position 4: K, position 7: K, position 35: K, position 40: V, position 43: E, position 46: A, position 53: D). EXAMPLES

[0090] To evaluate the relationship between the substitution of amino acid residues in the ligand and the binding strength to the pI-modified antibody, the KD values ​​of antibody A were measured for several ligand dimers using a method similar to that used in Example 2 (except that Lys:Biotin was changed to 12:1). The ligand dimers tested have a dimeric structure consisting of a ligand monomer with an R2' structure in which the amino acid residues at positions 40, 43, 46, and 53 of the C domain variant are replaced with lysine residues (K), and a ligand monomer in which position 42 of the C domain variant is replaced with an alanine residue (A), and positions 49, 50, and 58 are replaced with arginine residues (R) (hereinafter referred to as the "ligand monomer with an R1' structure"), and further have mutations at positions 4, 7, and 35. The results in Table 5 show that all of the dimers in which the lysine residue at position 4 (K) was replaced with either a valine residue (V), an isoleucine residue (I), a glutamic acid residue (E), or an arginine residue (R) showed enhanced affinity for antibody A.

[0091] [Table 5] *Denotes no substitutions for C domain variants (position 40: V, position 43: E, position 46: A, position 53: D, position 42: K, position 49: K, position 50: K, position 58: K). EXAMPLES

[0092] To evaluate the relationship between the addition of polylysine residues (K) to the ligand monomer and the binding strength to the pI-modified antibody, the KD value of antibody A was measured using a method similar to that in Example 2 (except that the Lys:Biotin ratio was changed to 12:1). The ligand monomer to be tested has an R1' structure in which the original lysine residues at positions 42, 49, 50, and 58 are replaced with amino acids other than lysine, and five lysine residues (K) are added to the C-terminus of the ligand monomer for immobilization on a carrier. The results in Table 6 show that in a ligand monomer in which the original lysine residues at positions 42, 49, 50, and 58 were replaced with alanine residues other than lysine (A) and arginine residues (R) and multiple lysine residues (K) were added to the C-terminus, the affinity for antibody A was enhanced by replacing position 35 with an arginine residue.

[0093] [Table 6] [Industrial Applicability]

[0094] By using a specific Protein A affinity column according to the present invention, it is possible to efficiently and simply purify pI-modified antibodies that cannot be purified using Protein A columns that are typically used in industrial production processes. The present invention is useful for stable and efficient industrial production of antibody pharmaceuticals.

Claims

1. 1. A method for purifying an IgG antibody comprising amino acid substitutions of Q311R and P343R from a composition comprising the antibody, comprising: (a) providing an affinity column comprising a carrier on which a modified Protein A ligand comprising a multimer of a modified immunoglobulin binding domain is immobilized; (b) loading the composition containing the IgG antibody onto the affinity column of step (a); and (c) eluting and recovering the IgG antibody from the affinity column of step (b); The IgG antibody comprises a heavy chain constant region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 12-57, The modified immunoglobulin-binding domain multimer has binding ability to an IgG antibody containing substitutions of amino acid residues Q311R and P343R, and is represented by the following formula (1) in which the left side is the N-terminus and the right side is the C-terminus: (R1)n-(R2)m or (R2)m-(R1)n (1), Where: (A) R1 and R2 are, respectively, a modified C domain of Staphylococcus protein A defined in SEQ ID NO: 1 or a Z domain defined in SEQ ID NO: 2, (i) containing a substitution of the lysine residue at position 35 with an arginine or glutamine residue; (ii) containing a substitution of the lysine residue at position 4 with an alanine residue, a valine residue, an isoleucine residue, an arginine residue, or a glutamic acid residue, and a substitution of the lysine residue at position 35 with an arginine residue, a glutamine residue, or a valine residue; or (iii) substitution of the lysine residue at position 4 with an alanine residue, a valine residue, an isoleucine residue, an arginine residue, or a glutamic acid residue, substitution of the lysine residue at position 7 with a tyrosine residue, a phenylalanine residue, a glutamine residue, a leucine residue, a isoleucine residue, a proline residue, a threonine residue, an alanine residue, a valine residue, an arginine residue, or a histidine residue, and substitution of the lysine residue at position 35 with an arginine residue, a glutamine residue, or a valine residue; (B) n is an integer of 1 or more and 9 or less, (C) m is 1 or 2; (D) the sum of n and m is 2 to 10; (E) the n R1 domains may or may not be identical in sequence to each other; and (F) the m R2 domains may or may not be identical in sequence to each other; A method which is a multimer of engineered immunoglobulin binding domains.

2. The method according to claim 1, wherein R1 or R2 is a modified C domain of Staphylococcus protein A defined in SEQ ID NO: 1 or a Z domain defined in SEQ ID NO: 2, respectively, comprising a substitution of the lysine residue at position 4 with an alanine residue, a substitution of the lysine residue at position 7 with a threonine residue, and a substitution of the lysine residue at position 35 with an arginine residue.

3. The method of claim 1 or 2, wherein R1 or R2 further comprises one to four of the following substitutions: substitution of the lysine residue at position 42 with an alanine residue, substitution of the lysine residue at position 49 with an arginine residue, substitution of the lysine residue at position 50 with an arginine residue, and substitution of the lysine residue at position 58 with an arginine residue.

4. The method of claim 1 or 2, wherein R1 or R2 further comprises substitution of the lysine residue at position 42 with an alanine residue, substitution of the lysine residue at position 49 with an arginine residue, substitution of the lysine residue at position 50 with an arginine residue, and substitution of the lysine residue at position 58 with an arginine residue.

5. The method according to any one of claims 1 to 4, wherein the first and / or second R1 and / or R2 from the N-terminus or C-terminus further comprises substitution of at least one of the originally existing amino acid residues at positions 40, 43, 46, 53, 54 and 56 with a lysine residue.

6. The method described in claim 5, wherein the first and / or second R1 and / or R2 from the N-terminus or C-terminus further includes substitution of the original amino acid residues at positions 40, 43, 46 and 53 with lysine residues.

7. The method described in any one of claims 1 to 6, wherein the modified immunoglobulin-binding domain multimer is a modified immunoglobulin-binding domain multimer in which R1 has the amino acid sequence shown in SEQ ID NO: 5 and R2 has the amino acid sequence shown in SEQ ID NO:

4.

8. The method of claim 1, wherein the modified immunoglobulin binding domain is a multimer, wherein n is 5 and m is 1.

9. The method according to any one of claims 1 to 8, wherein the protein A modified ligand is immobilized on the carrier by any one of the following means (1) to (5): (1) A method of immobilizing the protein A on a carrier via a modified immunoglobulin-binding domain in which one to six of the amino acid residues at positions 40, 43, 46, 53, 54, and 56 in the modified C domain or Z domain of protein A have been additionally substituted with lysine residues; (2) A method in which cysteine ​​is introduced at the C-terminus of Protein A and immobilized to a carrier via a disulfide bond or a thioether bond; (3) A method of immobilizing the thiol group on an amino group-containing solid support by cyanating the thiol group; and (4) A method of immobilizing a multimer of a modified immunoglobulin binding domain having cysteine ​​residues to an amino group-containing support using 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) as a crosslinking agent; (5) A method of immobilizing a modified immunoglobulin-binding domain to a carrier via multiple lysine residues added to the C-terminus of a modified immunoglobulin-binding domain in which the lysine residues at positions 42, 49, 50, and 58 of a modified Protein A C domain have been replaced with amino acids other than lysine, or a modified immunoglobulin-binding domain in which the lysine residues at positions 49, 50, and 58 of the Z domain have been replaced with amino acids other than lysine.

10. The method according to any one of claims 1 to 9, wherein the antibody has a pI value of 4.0 to 10.0.

Citation Information

Patent Citations

  • Purified immunoglobulin

    JP1993504579A

  • Affinity ligand for immunoglobulin

    JP2007252368A

  • Protein mutation type protein having improved dissociation property in weakly acidic region and antibody scavenger

    JP2010081866A

  • Method for control of blood kinetics of antibody

    WO2007114319A1

  • Immunoglobulin-binding domain multimer

    WO2015034000A1